论文部分内容阅读
目的探讨不同病理类型卵巢透明细胞癌的临床特征及预后。方法收集60例卵巢透明细胞癌患者的临床病理资料,比较子宫内膜异位症来源透明细胞癌(内异症组20例)、单纯透明细胞癌(单纯组31例)及合并其他病理类型(混合组9例)临床病理特征。结果 60例患者中,内异症组20例(33.3%),其中FIGOⅠ~Ⅱ期18例(90.0%),Ⅲ~Ⅳ期2例(10.0%),接受化疗17例,其中16例(94.1%)对化疗敏感;单纯组31例(51.7%),其中Ⅰ~Ⅱ期23例(74.2%),Ⅲ~Ⅳ期8例(25.8%),28例接受化疗,其中24例(85.7%)对化疗敏感;混合组9例(15%),Ⅰ~Ⅱ期4例(44.4%),Ⅲ~Ⅳ期5例(55.6%),对化疗敏感7例(77.8%)。单纯组中位生存时间[53个月(1~154个月)]与内异症组[67个月(21~99个月)]及混合组[46个月(13~163个月)]比较,差异均无统计学意义(P>0.05)。结论卵巢透明细胞癌的预后可能与病理类型相关,是否内异症来源透明细胞癌的生存时间差异需进一步研究。
Objective To investigate the clinical characteristics and prognosis of ovarian clear cell carcinoma of different pathological types. Methods The clinical and pathological data of 60 patients with clear cell carcinoma of the ovary were collected and compared with those of clear cell carcinoma of endometriosis (endometriosis group, 20 cases), simple clear cell carcinoma (31 cases of simple group) and other pathological types Mixed group of 9 cases) clinical and pathological features. Results Among the 60 patients, 20 cases (33.3%) had endometriosis, of which 18 cases (90.0%) were in FIGO Ⅰ ~ Ⅱ stage and 2 cases (10.0%) in Ⅲ ~ Ⅳ stage. 17 cases were treated with chemotherapy, of which 16 cases (94.1 %) Were sensitive to chemotherapeutics; in simple group, 31 cases (51.7%) had 23 cases (74.2%) in stage Ⅰ ~ Ⅱ and 8 (Ⅲ) Sensitive to chemotherapy; 9 patients (15%) in mixed group, 4 patients (44.4%) in stage Ⅰ ~ Ⅱ, 5 patients (55.6%) in stage Ⅲ ~ Ⅳ and 7 patients (77.8%) were sensitive to chemotherapy. The median survival time in the simple group (53 months (1 to 154 months) and endometriosis group (67 months [21 to 99 months]] and mixed group [46 months (13 to 163 months) There was no significant difference between the two groups (P> 0.05). Conclusions The prognosis of clear cell carcinoma of the ovary may be related to the pathological type. Whether the difference of the survival time of clear cell carcinoma with endometriosis needs further study.